Navigation Links
Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Date:2/12/2008

TUSTIN, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted therapies for the treatment of cancer and hepatitis C virus infection (HCV), today announced that patient dosing has begun in its clinical trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with advanced breast cancer. The primary objective of the study is to assess the overall response rate to the combination of bavituximab with docetaxel, a chemotherapy drug commonly used in breast cancer. The multicenter clinical trial is being conducted in the Republic of Georgia.

"We are now seeing good overall momentum in our bavituximab Phase II cancer program, and we are very pleased that our clinical colleagues in Europe have been so efficient in rapidly moving from protocol approval to trial initiation to patient dosing," said Steven W. King, president and CEO of Peregrine. "We are optimistic that all three bavituximab Phase II cancer trials will proceed well in the coming months and we look forward to reporting on our progress later this year."

In the trial's two-stage design, up to 15 patients with advanced breast cancer will be enrolled initially. The study will then be expanded up to a total of 46 patients if promising results are observed. Secondary objectives include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. Patients may continue to receive bavituximab alone after completion of chemotherapy as long as the cancer does not progress and side effects are acceptable.

"Bavituximab represents a novel strategy for the treatment of cancer that has
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
2. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
3. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
6. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
11. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... October 27, 2014 The report ... Intelligent Traffic Management, Communication, Monitoring), and by Display ... to 2019” segments the global market into various ... It also identifies the drivers and restraints for ... challenges. , Browse 75 market tables and 37 ...
(Date:10/27/2014)... Pa. , Oct. 27, 2014 ... Foundation of America (CCFA) announced today the launch ... , an educational campaign designed to ... diseases (IBD) on the paired role of nutrition ... To view the multimedia assets associated with this ...
(Date:10/26/2014)... (PRWEB) October 26, 2014 The ... Routers, ADC, Network Security Equipment, WAN Optimization Appliances]: ... and segments the data center networking market into ... of revenues. The report also identifies the factors ... opportunities impacting it along with the future roadmaps. ...
(Date:10/25/2014)... 25, 2014 The report “Adipic ... by Geography - Global Trends & Forecast to ... respect to market drivers, opportunities, and trends in ... and 27 figures spread through 217 slides and ... Trends & Forecast to 2019”., http://www.marketsandmarkets.com/Market-Reports/adipic-acid-269.html , ...
Breaking Biology Technology:Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 2Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 3Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 4Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 2Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 3Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 4Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 2Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 3Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 4Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 2Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 3Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 4
... Quarter 2009 Financial ResultsVANCOUVER, April 16 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, ... a conference call discussing its financial results for the first ... at 11:00 AM ET (8:00 AM Pacific)., ... is as, follows:, North ...
... Aspheric NTIOL Implanted through the Smallest Micro-Incision using ... Assist Ophthalmic PracticesMONROVIA, Calif., April 16 STAAR ... leading developer, manufacturer and marketer of minimally invasive ... Afinity Collamer Aspheric Single Piece New Technology Intraocular ...
... April 15 Cytopia Limited (ASX: CYT) announced that ... agent (VDA) CYT997 at the forthcoming 100th Annual Meeting ... Colorado, USA. Dr David Segal, Principal Scientist at Cytopia, ... Research: Experimental and Molecular Therapeutics 2 poster session ...
Cached Biology Technology:STAAR Surgical Releases Afinity(TM) Collamer(R) Aspheric Single Piece NTIOL 2STAAR Surgical Releases Afinity(TM) Collamer(R) Aspheric Single Piece NTIOL 3STAAR Surgical Releases Afinity(TM) Collamer(R) Aspheric Single Piece NTIOL 4STAAR Surgical Releases Afinity(TM) Collamer(R) Aspheric Single Piece NTIOL 5Cytopia Presentation on VDA CYT997 at AACR Conference 2
(Date:10/29/2014)... ceremony held in New York City on September 19, ... American Cancer Society Professor of Genome Sciences and Medicine ... Honorary Doctor of Philosophy of Tel Aviv University, was ... Science. , In addition to her honorary degree from ... the TAU School of Medicine, and for the past ...
(Date:10/29/2014)... One kind of stem cell, those referred to as ... There is apparently nothing that differentiates these cells from ... namely they retain the capacity to become stem cells ... liver, an organ that hosts cells that stimulate tissue ... the case of a transplant. Knowledge of the ...
(Date:10/29/2014)... living world compete with members of their own ... they invest into their competitive ability. Some individuals ... to high-quality resources, while others seem to avoid ... resources that are left over for them. Moreover, ... societies seems to fluctuate considerably over time. A ...
Breaking Biology News(10 mins):Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2A mechanism that allows a differentiated cell to reactivate as a stem cell revealed 2Evolution of competitiveness 2Evolution of competitiveness 3
... international collaborators have discovered the key to overcoming three ... growers worldwide in excess of AUS$7.8 billion. In ... Science , scientists from CSIRO Plant Industry, the University ... Center have identified a wheat gene sequence which provides ...
... Cardiovascular Research Institute, Colchester, Vermont have found that ... inhibitor type-1 (PAI-1) is profibrotic. The results, ... Experimental Biology and Medicine , implicate PAI-1 ... 2 diabetes, as a factor contributing to the ...
... Princeton, NJ February 23, 2009 - A new ... the Intergovernmental Panel on Climate Change (IPCC) 2001 Third ... increase in average global temperatures due to greenhouse gas ... of global concern. The study, published in the ...
Cached Biology News:Saving wheat crops worldwide 2Plasminogen activator inhibitor type-1 -- a potential link between heart failure and diabetes 2Lower increases in global temps could lead to greater impacts than previously thought, study finds 2Lower increases in global temps could lead to greater impacts than previously thought, study finds 3
...
Jak3 Antibody Ship: Hot Store: -20 C...
WASF2 Immunogen: WASF2 (NP_008921, 73 a.a. ~ 173 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Applications: Western blotting Stability: Room temperature, indefinitely ...
Biology Products: